Vitreo-retinal traction and anastrozole use.
OBJECTIVE
This study tested a prediction stemming from the hypothesis that anastrozole users experience heightened vitreo-retinal traction. This hypothesis was based on the knowledge that menopause increases the risk of intraocular tractional events such as posterior vitreous detachments (PVDs).


METHODS
Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication. Foveal shape indices were derived for subjects without PVDs.


RESULTS
For anastrozole users, the distance to the temporal side of the fovea became less than the distance to the nasal side at a sufficient height above the foveal base. This effect did not exist for control subjects; the between-group difference was appreciable. Results concerning tamoxifen users were inconclusive.


CONCLUSIONS
The foveas of women using anastrozole appear to be subjected to more tractional force than are the foveas of women not using any hormonal medication.
Eisner
Alvin
A
Casey Eye Institute, Oregon Health & Science University, Portland, USA. eisnera@ohsu.edu
Thielman
Emily J
EJ
Falardeau
Julie
J
Vetto
John T
JT
D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D005584:Fovea Centralis / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000009:adverse effects*; D013629:Tamoxifen / Q000009:adverse effects; D041623:Tomography, Optical Coherence; D014230:Triazoles / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole